KR20220075343A - 접합된 헵시딘 모방체 - Google Patents

접합된 헵시딘 모방체 Download PDF

Info

Publication number
KR20220075343A
KR20220075343A KR1020227011086A KR20227011086A KR20220075343A KR 20220075343 A KR20220075343 A KR 20220075343A KR 1020227011086 A KR1020227011086 A KR 1020227011086A KR 20227011086 A KR20227011086 A KR 20227011086A KR 20220075343 A KR20220075343 A KR 20220075343A
Authority
KR
South Korea
Prior art keywords
seq
hepcidin
subject
pharmaceutically acceptable
isovaleric acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227011086A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 와이. 리우
그레고리 토마스 본
루파 타라나스
수닐 쿠마르 굽타
니쉬트 바추랄 모디
Original Assignee
프로타고니스트 테라퓨틱스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프로타고니스트 테라퓨틱스, 인코포레이티드 filed Critical 프로타고니스트 테라퓨틱스, 인코포레이티드
Publication of KR20220075343A publication Critical patent/KR20220075343A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020227011086A 2019-09-03 2020-09-03 접합된 헵시딘 모방체 Pending KR20220075343A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962895201P 2019-09-03 2019-09-03
US62/895,201 2019-09-03
US202062983515P 2020-02-28 2020-02-28
US62/983,515 2020-02-28
US202063020945P 2020-05-06 2020-05-06
US63/020,945 2020-05-06
US202063059747P 2020-07-31 2020-07-31
US63/059,747 2020-07-31
PCT/US2020/049244 WO2021046246A1 (en) 2019-09-03 2020-09-03 Conjugated hepcidin mimetics

Publications (1)

Publication Number Publication Date
KR20220075343A true KR20220075343A (ko) 2022-06-08

Family

ID=74681239

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227011086A Pending KR20220075343A (ko) 2019-09-03 2020-09-03 접합된 헵시딘 모방체

Country Status (16)

Country Link
US (2) US20220372099A1 (https=)
EP (2) EP4025592B1 (https=)
JP (2) JP7831841B2 (https=)
KR (1) KR20220075343A (https=)
CN (1) CN114729022A (https=)
AU (1) AU2020343328B2 (https=)
BR (1) BR112022003999A2 (https=)
CA (1) CA3152789A1 (https=)
DK (1) DK4025592T3 (https=)
ES (1) ES3058577T3 (https=)
FI (1) FI4025592T3 (https=)
IL (1) IL291030A (https=)
MX (1) MX2022002633A (https=)
PH (1) PH12022550510A1 (https=)
PL (1) PL4025592T3 (https=)
WO (1) WO2021046246A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4091624A1 (en) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
HRP20211448T1 (hr) 2014-05-16 2021-12-24 Protagonist Therapeutics, Inc. Alfa4beta7 integrin tioeter peptidni antagonisti
CN107206254B (zh) 2014-07-17 2021-08-24 领导医疗有限公司 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途
US20190002503A1 (en) 2015-12-30 2019-01-03 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
CA3089868A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
WO2020014646A1 (en) 2018-07-12 2020-01-16 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
AU2021209086A1 (en) 2020-01-15 2022-08-04 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
CA3167751A1 (en) 2020-01-15 2021-07-22 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
JP7397239B2 (ja) 2020-11-20 2023-12-12 ヤンセン ファーマシューティカ エヌ．ベー． インターロイキン－２３受容体のペプチド阻害剤の組成物
AU2022249095A1 (en) * 2021-04-01 2023-10-12 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
IL309166A (en) * 2021-06-14 2024-02-01 Protagonist Therapeutics Inc Pasidine mimesis for the treatment of hereditary hemochromatosis
EP4370146A4 (en) 2021-07-14 2025-05-21 Janssen Biotech, Inc. Lipidated peptide inhibitors of the interleukin-23 receptor
EP4472996A4 (en) * 2022-02-02 2025-11-26 Protagonist Therapeutics Inc Conjugated hepcidin mimetics
EP4472995A4 (en) * 2022-02-02 2025-11-19 Protagonist Therapeutics Inc Conjugated hepcidin mimetics
WO2024011188A1 (en) * 2022-07-07 2024-01-11 Protagonist Therapeutics, Inc. Combination therapy for treatment of iron overload diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
CZ20013018A3 (cs) 1999-03-17 2002-02-13 Novo Nordisk A/S Způsob pro acylování aminoskupiny peptidu nebo proteinu a sloučenina
US7094785B1 (en) * 2002-12-18 2006-08-22 Cornell Research Foundation, Inc. Method of treating polycythemia vera
CA2677932A1 (en) 2007-02-15 2008-08-21 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
EP4091624A1 (en) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
EP3129040A4 (en) 2014-04-07 2018-03-21 La Jolla Pharmaceutical Company Hepdicin mimetic peptides and uses thereof
WO2015200916A2 (en) 2014-06-27 2015-12-30 Protagonist Therapeutics, Inc. Hepcidin and mini-hepcidin analogues and uses therof
UA123219C2 (uk) 2015-10-23 2021-03-03 Віфор (Інтернаціональ) Аґ Інгібітори феропортину
US20190002503A1 (en) 2015-12-30 2019-01-03 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
EP3509621A4 (en) 2016-09-06 2020-06-17 La Jolla Pharmaceutical Company METHODS OF TREATING IRON OVERLOAD
WO2018128828A1 (en) * 2016-12-23 2018-07-12 Bayer Healthcare Llc Novel hepcidin mimetics and uses thereof
CA3089868A1 (en) * 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics

Also Published As

Publication number Publication date
CA3152789A1 (en) 2021-03-11
MX2022002633A (es) 2022-06-02
AU2020343328A1 (en) 2022-04-07
US20220372099A1 (en) 2022-11-24
AU2020343328B2 (en) 2026-04-09
ES3058577T3 (en) 2026-03-11
CN114729022A (zh) 2022-07-08
FI4025592T3 (fi) 2026-01-30
JP2025163134A (ja) 2025-10-28
EP4025592B1 (en) 2025-10-29
PL4025592T3 (pl) 2026-03-16
EP4025592A1 (en) 2022-07-13
EP4706671A3 (en) 2026-04-01
DK4025592T3 (da) 2026-02-09
IL291030A (en) 2022-05-01
WO2021046246A1 (en) 2021-03-11
PH12022550510A1 (en) 2023-09-04
EP4025592A4 (en) 2023-08-02
JP7831841B2 (ja) 2026-03-17
EP4706671A2 (en) 2026-03-11
BR112022003999A2 (pt) 2022-05-31
US20210061872A1 (en) 2021-03-04
JP2022546878A (ja) 2022-11-09

Similar Documents

Publication Publication Date Title
EP4025592B1 (en) Conjugated hepcidin mimetics for use in treating of polycythemia vera
US12269856B2 (en) Hepcidin analogues and uses thereof
US11472842B2 (en) Analogues of hepcidin mimetics with improved in vivo half lives
WO2022026633A1 (en) Conjugated hepcidin mimetics
KR20170043509A (ko) 헵시딘 및 미니-헵시딘 유사체 및 그의 용도
WO2019157268A1 (en) Conjugated hepcidin mimetics
WO2022212698A1 (en) Conjugated hepcidin mimetics
EA048412B1 (ru) Конъюгированные миметики гепсидина

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902